US biotech giant Gilead Sciences (Nasdaq: GILD) has announced 48-week results from a Phase III study to evaluate the safety and efficacy of switching treatments for virologically suppressed HIV-1 adult patients.
Study 1089 replaced drug regimens containing emtricitabine and tenofovir disoproxil fumarate (F/TDF) (Truvada) with fixed-dose combinations of emtricitabine and tenofovir alafenamide (200/10mg and 200/25mg) (F/TAF).
The F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze